drugset
drugset / Trial / NCT03605082

A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

NCT03605082 ↗

Phase 1 Completed 24 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of the study is to evaluate the safety and tolerability and serum Pharmacokinetics (PK) of single doses of UCB0107 administered in healthy Japanese subjects.

Timeline

Start
2018-07-25
Primary completion
2019-03-11
Completion
2019-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject bepranemab Monoclonal antibody — Intravenous

Indications

No indication recorded.